2015 News Releases

Webcast ImageWebcast
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference  (Live)
05/03/17 at 4:10 p.m. ET
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference
Wednesday, May 3, 2017 4:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/14/15Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration
Alpharetta, GA (December 14, 2015) - Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced completion of enrollment in the company’s Phase 2 clinical trial (Tanzanite) for the treatment of macular edema associated with retinal vein occlusion (RVO).  The trial uses CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, injected by suprachoroidal space (SC... 
Printer Friendly Version
12/07/15Clearside Biomedical, Inc. Enrolls First Patient in Phase 3 Clinical Trial of CLS-TA Using Suprachoroidal Drug Administration
First Patient Randomized in Six-Month Efficacy Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis   Alpharetta, GA (December 7, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that the first patient was enrolled in Clearside’s Phase 3 clinical trial, Peachtree, of CLS-TA, Clearside’s proprietary form of triamcinolone acetoni... 
Printer Friendly Version
12/03/15Clearside Biomedical, Inc. Completes $20 Million Series C Financing
Alpharetta, GA (December 3, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the closing of a $20 million Series C financing.  The financing included new investors Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital Management, along with existing Clearside investors.  Trout Capital LLC served as an advisor to C... 
Printer Friendly Version
11/12/15Clearside Biomedical, Inc. Announces Fifth Patent Issued in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices
Alpharetta, GA (November 12, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 14/523,243 as U.S. Patent No. 9,180,047 in a patent titled, "Apparatus and Methods for Ocular Injection."   U.S. Patent No. 9,180,047 relates to methods for ocular injection and expands Clearside’s ... 
Printer Friendly Version
10/12/15Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space (SCS™) Drug Administration
For the Treatment of Macular Edema Associated with Non-Infectious Uveitis   Alpharetta, GA (October 12, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced completion of enrollment in the company’s Phase 2 clinical trial (Dogwood) of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using SCS™ drug administration for the treatment of macular ... 
Printer Friendly Version
09/24/15Clearside Biomedical, Inc. Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration
Major Milestone for Innovative Ophthalmic Drug Administration Platform Alpharetta, GA (September 24, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the retina and choroid, today announced the enrollment of the 50th patient using Clearside’s proprietary ophthalmic drug administration platform for delivering drugs to the suprachoroidal space (SCS).   Clearside’s SCS™ microinjec... 
Printer Friendly Version
09/22/15Clearside Biomedical, Inc. to Present at the 13th Congress of International Ocular Inflammation Society (IOIS) in San Francisco, CA
Hosted by the Foster Ocular Immunology Society (FOIS) Alpharetta, GA (September 22, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies uniquely positioned to treat blinding diseases of the retina and choroid, today announced Glenn Noronha, PhD, executive vice president of Research and Development of Clearside, will present a poster at the 13th Congress of International Ocular Inflammation Society (IOIS) September 25-27, 2015 i... 
Printer Friendly Version
07/09/15Clearside Biomedical, Inc. to Present at International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical Meeting
Alpharetta, GA (July 9, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced Glenn Noronha, PhD, executive vice president of Research and Development of Clearside, will present at the 2015 International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical meeting in Berlin, Germany on Friday, July 10.  Dr. Noronha’s presentation “Using sup... 
Printer Friendly Version
06/16/15Clearside Biomedical, Inc. Announces Favorable End-of-Phase 2 Review with the FDA
Plans to initiate a Phase 3 clinical study for the treatment of macular edema associated with non-infectious uveitis using proprietary administration through the suprachoroidal space (SCS) of the eye   Alpharetta, GA (June 16, 2015) – Clearside Biomedical, Inc., a biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced a favorable End-of-Phase 2 review with the U.S. Food and Drug Administration (FDA) on its lead drug tria... 
Printer Friendly Version
05/04/15Clearside Biomedical, Inc. and Santen, Inc. Announce Research Collaboration in Glaucoma
Expands Previous Research Collaboration to Include 2nd Largest Ophthalmic Market   Alpharetta, GA and Emeryville, CA (May 4, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, and Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd., today announced the expansion of their research collaboration to include the field of glaucoma.  The two companies have been... 
Printer Friendly Version
04/29/15Clearside Biomedical, Inc. to Report Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide at 2015 ARVO Meeting
Alpharetta, GA (April 29, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their Phase 1/2 clinical trial will be presented at the 2015 Annual Meeting of the Association for Research and Vision in Ophthalmology (ARVO), May 3-7, 2015, in Denver, CO. Debra Goldstein, MD, Professor of Ophthalmology and Director, Uveitis Service at the Northwestern Universi... 
Printer Friendly Version
04/22/15Clearside Biomedical, Inc. Announces Purchase of iScience Patent Portfolio for Suprachoroidal Space Drug Delivery
Alpharetta, GA (April 22, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the purchase and acquisition of iScience Interventional Corporation’s patent portfolio covering drug delivery to the suprachoroidal space (SCS).  The iScience SCS patent portfolio includes United States and international patents and patent applications.  The purchased portfoli... 
Printer Friendly Version
03/16/15Clearside Biomedical, Inc. Reports Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide
Patients Treated in the Clinical Trial Exhibited Improvement in Best Corrected Visual Acuity No Meaningful Increases in IOP Observed; No Patient Required IOP-lowering Medication   Alpharetta, GA (March 16, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the efficacy and safety results from Clearside’s recently completed six-month Phase 1/2 clinical trial.&nbs... 
Printer Friendly Version
03/02/15Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion
Follows the recent initiation of Clearside’s Phase 2 clinical trial for the treatment of macular edema associated with non-infectious uveitis   Alpharetta, GA (March 2, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of  macular edema... 
Printer Friendly Version
01/05/15Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis
Alpharetta, GA (January 5, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of  macular edema associated with non-infectious uveitis using Clearside’s proprietary formulation of triamcinolone acetonide, CLS-TA, administered via suprachoroidal... 
Printer Friendly Version